Downstream Processing Featured Articles

31. New Look At Multitalented Protein Sheds Light On Mysteries Of HIV 11/12/2012

    New insights into the human immunodeficiency virus (HIV) infection process, which leads to acquired immunodeficiency syndrome (AIDS), may now be possible through a research method recently developed in part at the National Institute of Standards and Technology (NIST), where scientists have glimpsed an important protein molecule's behavior with unprecedented clarity.

32. Pfenex Awarded Contract By The NIAID To Develop An Alternative Delivery Method For rPA-based Anthrax Vaccine 10/17/2012

    Pfenex Inc. Awarded Contract by the National Institute of Allergy and Infectious Diseases  (NIAID) to Develop an Alternative Delivery Method for its Recombinant Protective Antigen (rPA)-based Anthrax Vaccine

33. GSK Receives FDA Approval For MenHibrix 6/14/2012

    GlaxoSmithKline plc announced recently that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine]. 

34. Merck Assesses Single Use: Does It Make Sense At A Large Scale? 5/14/2014

    In an industry as conservative as the pharmaceutical industry, it is common practice to be adverse to new technologies because they are often viewed as too much of a risk. However, in this effort to play it safe, companies force themselves into a repetitive state of employing technologies that may not be the most efficient or effective. Rather than getting stuck in old habits — or conversely, jumping too quickly into new ones — Merck has put together a group of teams it calls the Technology Encouragement Collaborators, or TEC, to look at new technologies and determine whether or not to implement them.

35. International Stem Cell Corporation Demonstrates Positive Animal Efficacy Results In Metabolic Liver Disease Program 2/12/2013

    International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced the conclusions from its study demonstrating the efficacy and safety of the hepatocyte-like cells (HLC) derived from human parthenogenetic stem cells (hpSC) in a well-established animal model of a congenital liver disorder associated with bilirubin metabolism.

36. Thallion And LFB Terminate Shigamabs Collaboration 2/20/2013

    Thallion Pharmaceuticals Inc. (TSX-V: TLN) ("Thallion") and LFB Biotechnologies ("LFB") today announced that they have reached an agreement on the termination of their Development and Licensing Agreement related to Thallion's Shigamabs® program.

37. MorphoSys Receives First Patent On Novel Antibody Platform Ylanthia In The US 2/8/2013

    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and Trademark Office (USPTO) has granted the first patent covering the Company's latest antibody platform Ylanthia, which became commercially available for existing and new partners in 2012.

38. Tweaking Gene Expression To Repair Lungs 2/25/2013

    Lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are on the rise, according to the American Lung Association and the National Institutes of Health.

39. Brain Signal IDs Responders To Fast-Acting Antidepressant 8/3/2012

    Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

40. OHSU Doernbecher Scientists First To Grow Liver Stem Cells In Culture, Transplant Them With Demonstrated Therapeutic Benefit 2/25/2013

    For decades scientists around the world have attempted to regenerate primary liver cells known as hepatocytes because of their numerous biomedical applications, including hepatitis research, drug metabolism and toxicity studies, as well as transplantation for cirrhosis and other chronic liver conditions.